A PHASE 2B/3A, MULTI-CENTER, RDMZD, DOUBLE-BLIND, PLACEBO-CTRLLD, PARALLEL-GROUP STUDY OF THE EFFICACY & SAFETY OF AMAG-423, A DIGOXIN IMMUNE FAB, IN ANTEPARTUM SUBJECTS WITH SEVERE PREECLAMPSIA CTMS#: 19-0112
Principal Investigator(s)
Ramsey, Patrick S
Funded by
AMAG PHARMACEUTICALS, INC.
Research Start Date
Status
Active